The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Anti-Obesity Drugs (Anti-obesity Medication) Market Research Report 2025
Synopsis
Anti-obesity medication or weight loss medications are pharmacological agents that reduce or control weight. These medications alter one of the fundamental processes of the human body, weight regulation, by altering either appetite, or absorption of calories.
The global Anti-Obesity Drugs (Anti-obesity Medication) market was valued at US$ 1824.1 million in 2023 and is anticipated to reach US$ 5569.5 million by 2030, witnessing a CAGR of 17.0% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Anti-Obesity Drugs (Anti-obesity Medication), with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Anti-Obesity Drugs (Anti-obesity Medication).
Report Scope
The Anti-Obesity Drugs (Anti-obesity Medication) market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Anti-Obesity Drugs (Anti-obesity Medication) market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Anti-Obesity Drugs (Anti-obesity Medication) manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Zafgan
Vivus
Shionogi
Sanofi
Rhythm Pharmaceuticals
Pfizer
Orexigen Therapeutics
Novo Nordisk
Norgine
Nalpropion Pharmaceuticals Inc.
Merck
GlaxoSmithKline
F.Hoffmann-La Roche
Eisai
Boehringer Ingelheim
Bayer AG
AstraZeneca
Arena Pharmaceuticals
Amylin
Alizyme
Segment by Type
by Drug Varieties
Prescription Drugs
OTC Drugs
by Acting
Peripherally Acting Anti-obesity Drugs
Centrally Acting Anti-obesity Drugs
Segment by Application
Childhood (0-6)
Juvenile (7-17)
Youth (18-40)
Middle Aged (41-60)
Elderly (Above 60)
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Anti-Obesity Drugs (Anti-obesity Medication) manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Anti-Obesity Drugs (Anti-obesity Medication) in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Anti-obesity medication or weight loss medications are pharmacological agents that reduce or control weight. These medications alter one of the fundamental processes of the human body, weight regulation, by altering either appetite, or absorption of calories.
The global Anti-Obesity Drugs (Anti-obesity Medication) market was valued at US$ 1824.1 million in 2023 and is anticipated to reach US$ 5569.5 million by 2030, witnessing a CAGR of 17.0% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Anti-Obesity Drugs (Anti-obesity Medication), with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Anti-Obesity Drugs (Anti-obesity Medication).
Report Scope
The Anti-Obesity Drugs (Anti-obesity Medication) market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Anti-Obesity Drugs (Anti-obesity Medication) market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Anti-Obesity Drugs (Anti-obesity Medication) manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Zafgan
Vivus
Shionogi
Sanofi
Rhythm Pharmaceuticals
Pfizer
Orexigen Therapeutics
Novo Nordisk
Norgine
Nalpropion Pharmaceuticals Inc.
Merck
GlaxoSmithKline
F.Hoffmann-La Roche
Eisai
Boehringer Ingelheim
Bayer AG
AstraZeneca
Arena Pharmaceuticals
Amylin
Alizyme
Segment by Type
by Drug Varieties
Prescription Drugs
OTC Drugs
by Acting
Peripherally Acting Anti-obesity Drugs
Centrally Acting Anti-obesity Drugs
Segment by Application
Childhood (0-6)
Juvenile (7-17)
Youth (18-40)
Middle Aged (41-60)
Elderly (Above 60)
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Anti-Obesity Drugs (Anti-obesity Medication) manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Anti-Obesity Drugs (Anti-obesity Medication) in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 Anti-Obesity Drugs (Anti-obesity Medication) Market Overview
1.1 Product Overview and Scope of Anti-Obesity Drugs (Anti-obesity Medication)
1.2 Anti-Obesity Drugs (Anti-obesity Medication) Segment by Drug Varieties
1.2.1 Global Anti-Obesity Drugs (Anti-obesity Medication) Market Value Comparison by Drug Varieties (2024-2030)
1.2.2 Prescription Drugs
1.2.3 OTC Drugs
1.3 Anti-Obesity Drugs (Anti-obesity Medication) Segment by Application
1.3.1 Global Anti-Obesity Drugs (Anti-obesity Medication) Market Value by Application: (2024-2030)
1.3.2 Childhood (0-6)
1.3.3 Juvenile (7-17)
1.3.4 Youth (18-40)
1.3.5 Middle Aged (41-60)
1.3.6 Elderly (Above 60)
1.4 Global Anti-Obesity Drugs (Anti-obesity Medication) Market Size Estimates and Forecasts
1.4.1 Global Anti-Obesity Drugs (Anti-obesity Medication) Revenue 2019-2030
1.4.2 Global Anti-Obesity Drugs (Anti-obesity Medication) Sales 2019-2030
1.4.3 Global Anti-Obesity Drugs (Anti-obesity Medication) Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Anti-Obesity Drugs (Anti-obesity Medication) Market Competition by Manufacturers
2.1 Global Anti-Obesity Drugs (Anti-obesity Medication) Sales Market Share by Manufacturers (2019-2024)
2.2 Global Anti-Obesity Drugs (Anti-obesity Medication) Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Anti-Obesity Drugs (Anti-obesity Medication) Average Price by Manufacturers (2019-2024)
2.4 Global Anti-Obesity Drugs (Anti-obesity Medication) Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Anti-Obesity Drugs (Anti-obesity Medication), Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Anti-Obesity Drugs (Anti-obesity Medication), Product Type & Application
2.7 Anti-Obesity Drugs (Anti-obesity Medication) Market Competitive Situation and Trends
2.7.1 Anti-Obesity Drugs (Anti-obesity Medication) Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Anti-Obesity Drugs (Anti-obesity Medication) Players Market Share by Revenue
2.7.3 Global Anti-Obesity Drugs (Anti-obesity Medication) Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Anti-Obesity Drugs (Anti-obesity Medication) Retrospective Market Scenario by Region
3.1 Global Anti-Obesity Drugs (Anti-obesity Medication) Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Anti-Obesity Drugs (Anti-obesity Medication) Global Anti-Obesity Drugs (Anti-obesity Medication) Sales by Region: 2019-2030
3.2.1 Global Anti-Obesity Drugs (Anti-obesity Medication) Sales by Region: 2019-2024
3.2.2 Global Anti-Obesity Drugs (Anti-obesity Medication) Sales by Region: 2025-2030
3.3 Global Anti-Obesity Drugs (Anti-obesity Medication) Global Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Region: 2019-2030
3.3.1 Global Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Region: 2019-2024
3.3.2 Global Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Region: 2025-2030
3.4 North America Anti-Obesity Drugs (Anti-obesity Medication) Market Facts & Figures by Country
3.4.1 North America Anti-Obesity Drugs (Anti-obesity Medication) Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Anti-Obesity Drugs (Anti-obesity Medication) Sales by Country (2019-2030)
3.4.3 North America Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Country (2019-2030)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Anti-Obesity Drugs (Anti-obesity Medication) Market Facts & Figures by Country
3.5.1 Europe Anti-Obesity Drugs (Anti-obesity Medication) Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Anti-Obesity Drugs (Anti-obesity Medication) Sales by Country (2019-2030)
3.5.3 Europe Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Anti-Obesity Drugs (Anti-obesity Medication) Market Facts & Figures by Country
3.6.1 Asia Pacific Anti-Obesity Drugs (Anti-obesity Medication) Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Anti-Obesity Drugs (Anti-obesity Medication) Sales by Country (2019-2030)
3.6.3 Asia Pacific Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Anti-Obesity Drugs (Anti-obesity Medication) Market Facts & Figures by Country
3.7.1 Latin America Anti-Obesity Drugs (Anti-obesity Medication) Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Anti-Obesity Drugs (Anti-obesity Medication) Sales by Country (2019-2030)
3.7.3 Latin America Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Anti-Obesity Drugs (Anti-obesity Medication) Market Facts & Figures by Country
3.8.1 Middle East and Africa Anti-Obesity Drugs (Anti-obesity Medication) Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Anti-Obesity Drugs (Anti-obesity Medication) Sales by Country (2019-2030)
3.8.3 Middle East and Africa Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Anti-Obesity Drugs (Anti-obesity Medication) Sales by Type (2019-2030)
4.1.1 Global Anti-Obesity Drugs (Anti-obesity Medication) Sales by Type (2019-2024)
4.1.2 Global Anti-Obesity Drugs (Anti-obesity Medication) Sales by Type (2025-2030)
4.1.3 Global Anti-Obesity Drugs (Anti-obesity Medication) Sales Market Share by Type (2019-2030)
4.2 Global Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Type (2019-2030)
4.2.1 Global Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Type (2019-2024)
4.2.2 Global Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Type (2025-2030)
4.2.3 Global Anti-Obesity Drugs (Anti-obesity Medication) Revenue Market Share by Type (2019-2030)
4.3 Global Anti-Obesity Drugs (Anti-obesity Medication) Price by Type (2019-2030)
5 Segment by Application
5.1 Global Anti-Obesity Drugs (Anti-obesity Medication) Sales by Application (2019-2030)
5.1.1 Global Anti-Obesity Drugs (Anti-obesity Medication) Sales by Application (2019-2024)
5.1.2 Global Anti-Obesity Drugs (Anti-obesity Medication) Sales by Application (2025-2030)
5.1.3 Global Anti-Obesity Drugs (Anti-obesity Medication) Sales Market Share by Application (2019-2030)
5.2 Global Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Application (2019-2030)
5.2.1 Global Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Application (2019-2024)
5.2.2 Global Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Application (2025-2030)
5.2.3 Global Anti-Obesity Drugs (Anti-obesity Medication) Revenue Market Share by Application (2019-2030)
5.3 Global Anti-Obesity Drugs (Anti-obesity Medication) Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Zafgan
6.1.1 Zafgan Corporation Information
6.1.2 Zafgan Description and Business Overview
6.1.3 Zafgan Anti-Obesity Drugs (Anti-obesity Medication) Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Zafgan Anti-Obesity Drugs (Anti-obesity Medication) Product Portfolio
6.1.5 Zafgan Recent Developments/Updates
6.2 Vivus
6.2.1 Vivus Corporation Information
6.2.2 Vivus Description and Business Overview
6.2.3 Vivus Anti-Obesity Drugs (Anti-obesity Medication) Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Vivus Anti-Obesity Drugs (Anti-obesity Medication) Product Portfolio
6.2.5 Vivus Recent Developments/Updates
6.3 Shionogi
6.3.1 Shionogi Corporation Information
6.3.2 Shionogi Description and Business Overview
6.3.3 Shionogi Anti-Obesity Drugs (Anti-obesity Medication) Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Shionogi Anti-Obesity Drugs (Anti-obesity Medication) Product Portfolio
6.3.5 Shionogi Recent Developments/Updates
6.4 Sanofi
6.4.1 Sanofi Corporation Information
6.4.2 Sanofi Description and Business Overview
6.4.3 Sanofi Anti-Obesity Drugs (Anti-obesity Medication) Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Sanofi Anti-Obesity Drugs (Anti-obesity Medication) Product Portfolio
6.4.5 Sanofi Recent Developments/Updates
6.5 Rhythm Pharmaceuticals
6.5.1 Rhythm Pharmaceuticals Corporation Information
6.5.2 Rhythm Pharmaceuticals Description and Business Overview
6.5.3 Rhythm Pharmaceuticals Anti-Obesity Drugs (Anti-obesity Medication) Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Rhythm Pharmaceuticals Anti-Obesity Drugs (Anti-obesity Medication) Product Portfolio
6.5.5 Rhythm Pharmaceuticals Recent Developments/Updates
6.6 Pfizer
6.6.1 Pfizer Corporation Information
6.6.2 Pfizer Description and Business Overview
6.6.3 Pfizer Anti-Obesity Drugs (Anti-obesity Medication) Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Pfizer Anti-Obesity Drugs (Anti-obesity Medication) Product Portfolio
6.6.5 Pfizer Recent Developments/Updates
6.7 Orexigen Therapeutics
6.6.1 Orexigen Therapeutics Corporation Information
6.6.2 Orexigen Therapeutics Description and Business Overview
6.6.3 Orexigen Therapeutics Anti-Obesity Drugs (Anti-obesity Medication) Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Orexigen Therapeutics Anti-Obesity Drugs (Anti-obesity Medication) Product Portfolio
6.7.5 Orexigen Therapeutics Recent Developments/Updates
6.8 Novo Nordisk
6.8.1 Novo Nordisk Corporation Information
6.8.2 Novo Nordisk Description and Business Overview
6.8.3 Novo Nordisk Anti-Obesity Drugs (Anti-obesity Medication) Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Novo Nordisk Anti-Obesity Drugs (Anti-obesity Medication) Product Portfolio
6.8.5 Novo Nordisk Recent Developments/Updates
6.9 Norgine
6.9.1 Norgine Corporation Information
6.9.2 Norgine Description and Business Overview
6.9.3 Norgine Anti-Obesity Drugs (Anti-obesity Medication) Sales, Revenue and Gross Margin (2019-2024)
6.9.4 Norgine Anti-Obesity Drugs (Anti-obesity Medication) Product Portfolio
6.9.5 Norgine Recent Developments/Updates
6.10 Nalpropion Pharmaceuticals Inc.
6.10.1 Nalpropion Pharmaceuticals Inc. Corporation Information
6.10.2 Nalpropion Pharmaceuticals Inc. Description and Business Overview
6.10.3 Nalpropion Pharmaceuticals Inc. Anti-Obesity Drugs (Anti-obesity Medication) Sales, Revenue and Gross Margin (2019-2024)
6.10.4 Nalpropion Pharmaceuticals Inc. Anti-Obesity Drugs (Anti-obesity Medication) Product Portfolio
6.10.5 Nalpropion Pharmaceuticals Inc. Recent Developments/Updates
6.11 Merck
6.11.1 Merck Corporation Information
6.11.2 Merck Anti-Obesity Drugs (Anti-obesity Medication) Description and Business Overview
6.11.3 Merck Anti-Obesity Drugs (Anti-obesity Medication) Sales, Revenue and Gross Margin (2019-2024)
6.11.4 Merck Anti-Obesity Drugs (Anti-obesity Medication) Product Portfolio
6.11.5 Merck Recent Developments/Updates
6.12 GlaxoSmithKline
6.12.1 GlaxoSmithKline Corporation Information
6.12.2 GlaxoSmithKline Anti-Obesity Drugs (Anti-obesity Medication) Description and Business Overview
6.12.3 GlaxoSmithKline Anti-Obesity Drugs (Anti-obesity Medication) Sales, Revenue and Gross Margin (2019-2024)
6.12.4 GlaxoSmithKline Anti-Obesity Drugs (Anti-obesity Medication) Product Portfolio
6.12.5 GlaxoSmithKline Recent Developments/Updates
6.13 F.Hoffmann-La Roche
6.13.1 F.Hoffmann-La Roche Corporation Information
6.13.2 F.Hoffmann-La Roche Anti-Obesity Drugs (Anti-obesity Medication) Description and Business Overview
6.13.3 F.Hoffmann-La Roche Anti-Obesity Drugs (Anti-obesity Medication) Sales, Revenue and Gross Margin (2019-2024)
6.13.4 F.Hoffmann-La Roche Anti-Obesity Drugs (Anti-obesity Medication) Product Portfolio
6.13.5 F.Hoffmann-La Roche Recent Developments/Updates
6.14 Eisai
6.14.1 Eisai Corporation Information
6.14.2 Eisai Anti-Obesity Drugs (Anti-obesity Medication) Description and Business Overview
6.14.3 Eisai Anti-Obesity Drugs (Anti-obesity Medication) Sales, Revenue and Gross Margin (2019-2024)
6.14.4 Eisai Anti-Obesity Drugs (Anti-obesity Medication) Product Portfolio
6.14.5 Eisai Recent Developments/Updates
6.15 Boehringer Ingelheim
6.15.1 Boehringer Ingelheim Corporation Information
6.15.2 Boehringer Ingelheim Anti-Obesity Drugs (Anti-obesity Medication) Description and Business Overview
6.15.3 Boehringer Ingelheim Anti-Obesity Drugs (Anti-obesity Medication) Sales, Revenue and Gross Margin (2019-2024)
6.15.4 Boehringer Ingelheim Anti-Obesity Drugs (Anti-obesity Medication) Product Portfolio
6.15.5 Boehringer Ingelheim Recent Developments/Updates
6.16 Bayer AG
6.16.1 Bayer AG Corporation Information
6.16.2 Bayer AG Anti-Obesity Drugs (Anti-obesity Medication) Description and Business Overview
6.16.3 Bayer AG Anti-Obesity Drugs (Anti-obesity Medication) Sales, Revenue and Gross Margin (2019-2024)
6.16.4 Bayer AG Anti-Obesity Drugs (Anti-obesity Medication) Product Portfolio
6.16.5 Bayer AG Recent Developments/Updates
6.17 AstraZeneca
6.17.1 AstraZeneca Corporation Information
6.17.2 AstraZeneca Anti-Obesity Drugs (Anti-obesity Medication) Description and Business Overview
6.17.3 AstraZeneca Anti-Obesity Drugs (Anti-obesity Medication) Sales, Revenue and Gross Margin (2019-2024)
6.17.4 AstraZeneca Anti-Obesity Drugs (Anti-obesity Medication) Product Portfolio
6.17.5 AstraZeneca Recent Developments/Updates
6.18 Arena Pharmaceuticals
6.18.1 Arena Pharmaceuticals Corporation Information
6.18.2 Arena Pharmaceuticals Anti-Obesity Drugs (Anti-obesity Medication) Description and Business Overview
6.18.3 Arena Pharmaceuticals Anti-Obesity Drugs (Anti-obesity Medication) Sales, Revenue and Gross Margin (2019-2024)
6.18.4 Arena Pharmaceuticals Anti-Obesity Drugs (Anti-obesity Medication) Product Portfolio
6.18.5 Arena Pharmaceuticals Recent Developments/Updates
6.19 Amylin
6.19.1 Amylin Corporation Information
6.19.2 Amylin Anti-Obesity Drugs (Anti-obesity Medication) Description and Business Overview
6.19.3 Amylin Anti-Obesity Drugs (Anti-obesity Medication) Sales, Revenue and Gross Margin (2019-2024)
6.19.4 Amylin Anti-Obesity Drugs (Anti-obesity Medication) Product Portfolio
6.19.5 Amylin Recent Developments/Updates
6.20 Alizyme
6.20.1 Alizyme Corporation Information
6.20.2 Alizyme Anti-Obesity Drugs (Anti-obesity Medication) Description and Business Overview
6.20.3 Alizyme Anti-Obesity Drugs (Anti-obesity Medication) Sales, Revenue and Gross Margin (2019-2024)
6.20.4 Alizyme Anti-Obesity Drugs (Anti-obesity Medication) Product Portfolio
6.20.5 Alizyme Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Anti-Obesity Drugs (Anti-obesity Medication) Industry Chain Analysis
7.2 Anti-Obesity Drugs (Anti-obesity Medication) Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Anti-Obesity Drugs (Anti-obesity Medication) Production Mode & Process
7.4 Anti-Obesity Drugs (Anti-obesity Medication) Sales and Marketing
7.4.1 Anti-Obesity Drugs (Anti-obesity Medication) Sales Channels
7.4.2 Anti-Obesity Drugs (Anti-obesity Medication) Distributors
7.5 Anti-Obesity Drugs (Anti-obesity Medication) Customers
8 Anti-Obesity Drugs (Anti-obesity Medication) Market Dynamics
8.1 Anti-Obesity Drugs (Anti-obesity Medication) Industry Trends
8.2 Anti-Obesity Drugs (Anti-obesity Medication) Market Drivers
8.3 Anti-Obesity Drugs (Anti-obesity Medication) Market Challenges
8.4 Anti-Obesity Drugs (Anti-obesity Medication) Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
List of TablesList of Tables
Table 1. Global Anti-Obesity Drugs (Anti-obesity Medication) Market Value Comparison by Type (2024-2030) & (US$ Million)
Table 2. Global Anti-Obesity Drugs (Anti-obesity Medication) Market Value Comparison by Application (2024-2030) & (US$ Million)
Table 3. Global Anti-Obesity Drugs (Anti-obesity Medication) Market Competitive Situation by Manufacturers in 2023
Table 4. Global Anti-Obesity Drugs (Anti-obesity Medication) Sales (K Units) of Key Manufacturers (2019-2024)
Table 5. Global Anti-Obesity Drugs (Anti-obesity Medication) Sales Market Share by Manufacturers (2019-2024)
Table 6. Global Anti-Obesity Drugs (Anti-obesity Medication) Revenue (US$ Million) by Manufacturers (2019-2024)
Table 7. Global Anti-Obesity Drugs (Anti-obesity Medication) Revenue Share by Manufacturers (2019-2024)
Table 8. Global Market Anti-Obesity Drugs (Anti-obesity Medication) Average Price (USD/Unit) of Key Manufacturers (2019-2024)
Table 9. Global Key Players of Anti-Obesity Drugs (Anti-obesity Medication), Industry Ranking, 2022 VS 2023 VS 2024
Table 10. Global Key Manufacturers of Anti-Obesity Drugs (Anti-obesity Medication), Manufacturing Sites & Headquarters
Table 11. Global Key Manufacturers of Anti-Obesity Drugs (Anti-obesity Medication), Product Type & Application
Table 12. Global Key Manufacturers of Anti-Obesity Drugs (Anti-obesity Medication), Date of Enter into This Industry
Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 14. Global Anti-Obesity Drugs (Anti-obesity Medication) by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Anti-Obesity Drugs (Anti-obesity Medication) as of 2023)
Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 16. Global Anti-Obesity Drugs (Anti-obesity Medication) Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 17. Global Anti-Obesity Drugs (Anti-obesity Medication) Sales by Region (2019-2024) & (K Units)
Table 18. Global Anti-Obesity Drugs (Anti-obesity Medication) Sales Market Share by Region (2019-2024)
Table 19. Global Anti-Obesity Drugs (Anti-obesity Medication) Sales by Region (2025-2030) & (K Units)
Table 20. Global Anti-Obesity Drugs (Anti-obesity Medication) Sales Market Share by Region (2025-2030)
Table 21. Global Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Region (2019-2024) & (US$ Million)
Table 22. Global Anti-Obesity Drugs (Anti-obesity Medication) Revenue Market Share by Region (2019-2024)
Table 23. Global Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Region (2025-2030) & (US$ Million)
Table 24. Global Anti-Obesity Drugs (Anti-obesity Medication) Revenue Market Share by Region (2025-2030)
Table 25. North America Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 26. North America Anti-Obesity Drugs (Anti-obesity Medication) Sales by Country (2019-2024) & (K Units)
Table 27. North America Anti-Obesity Drugs (Anti-obesity Medication) Sales by Country (2025-2030) & (K Units)
Table 28. North America Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Country (2019-2024) & (US$ Million)
Table 29. North America Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Country (2025-2030) & (US$ Million)
Table 30. Europe Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 31. Europe Anti-Obesity Drugs (Anti-obesity Medication) Sales by Country (2019-2024) & (K Units)
Table 32. Europe Anti-Obesity Drugs (Anti-obesity Medication) Sales by Country (2025-2030) & (K Units)
Table 33. Europe Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Country (2019-2024) & (US$ Million)
Table 34. Europe Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Country (2025-2030) & (US$ Million)
Table 35. Asia Pacific Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 36. Asia Pacific Anti-Obesity Drugs (Anti-obesity Medication) Sales by Region (2019-2024) & (K Units)
Table 37. Asia Pacific Anti-Obesity Drugs (Anti-obesity Medication) Sales by Region (2025-2030) & (K Units)
Table 38. Asia Pacific Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Region (2019-2024) & (US$ Million)
Table 39. Asia Pacific Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Region (2025-2030) & (US$ Million)
Table 40. Latin America Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 41. Latin America Anti-Obesity Drugs (Anti-obesity Medication) Sales by Country (2019-2024) & (K Units)
Table 42. Latin America Anti-Obesity Drugs (Anti-obesity Medication) Sales by Country (2025-2030) & (K Units)
Table 43. Latin America Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Country (2019-2024) & (US$ Million)
Table 44. Latin America Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Country (2025-2030) & (US$ Million)
Table 45. Middle East & Africa Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)
Table 46. Middle East & Africa Anti-Obesity Drugs (Anti-obesity Medication) Sales by Country (2019-2024) & (K Units)
Table 47. Middle East & Africa Anti-Obesity Drugs (Anti-obesity Medication) Sales by Country (2025-2030) & (K Units)
Table 48. Middle East & Africa Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Country (2019-2024) & (US$ Million)
Table 49. Middle East & Africa Anti-Obesity Drugs (Anti-obesity Medication) Revenue by Country (2025-2030) & (US$ Million)
Table 50. Global Anti-Obesity Drugs (Anti-obesity Medication) Sales (K Units) by Type (2019-2024)
Table 51. Global Anti-Obesity Drugs (Anti-obesity Medication) Sales (K Units) by Type (2025-2030)
Table 52. Global Anti-Obesity Drugs (Anti-obesity Medication) Sales Market Share by Type (2019-2024)
Table 53. Global Anti-Obesity Drugs (Anti-obesity Medication) Sales Market Share by Type (2025-2030)
Table 54. Global Anti-Obesity Drugs (Anti-obesity Medication) Revenue (US$ Million) by Type (2019-2024)
Table 55. Global Anti-Obesity Drugs (Anti-obesity Medication) Revenue (US$ Million) by Type (2025-2030)
Table 56. Global Anti-Obesity Drugs (Anti-obesity Medication) Revenue Market Share by Type (2019-2024)
Table 57. Global Anti-Obesity Drugs (Anti-obesity Medication) Revenue Market Share by Type (2025-2030)
Table 58. Global Anti-Obesity Drugs (Anti-obesity Medication) Price (USD/Unit) by Type (2019-2024)
Table 59. Global Anti-Obesity Drugs (Anti-obesity Medication) Price (USD/Unit) by Type (2025-2030)
Table 60. Global Anti-Obesity Drugs (Anti-obesity Medication) Sales (K Units) by Application (2019-2024)
Table 61. Global Anti-Obesity Drugs (Anti-obesity Medication) Sales (K Units) by Application (2025-2030)
Table 62. Global Anti-Obesity Drugs (Anti-obesity Medication) Sales Market Share by Application (2019-2024)
Table 63. Global Anti-Obesity Drugs (Anti-obesity Medication) Sales Market Share by Application (2025-2030)
Table 64. Global Anti-Obesity Drugs (Anti-obesity Medication) Revenue (US$ Million) by Application (2019-2024)
Table 65. Global Anti-Obesity Drugs (Anti-obesity Medication) Revenue (US$ Million) by Application (2025-2030)
Table 66. Global Anti-Obesity Drugs (Anti-obesity Medication) Revenue Market Share by Application (2019-2024)
Table 67. Global Anti-Obesity Drugs (Anti-obesity Medication) Revenue Market Share by Application (2025-2030)
Table 68. Global Anti-Obesity Drugs (Anti-obesity Medication) Price (USD/Unit) by Application (2019-2024)
Table 69. Global Anti-Obesity Drugs (Anti-obesity Medication) Price (USD/Unit) by Application (2025-2030)
Table 70. Zafgan Corporation Information
Table 71. Zafgan Description and Business Overview
Table 72. Zafgan Anti-Obesity Drugs (Anti-obesity Medication) Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 73. Zafgan Anti-Obesity Drugs (Anti-obesity Medication) Product
Table 74. Zafgan Recent Developments/Updates
Table 75. Vivus Corporation Information
Table 76. Vivus Description and Business Overview
Table 77. Vivus Anti-Obesity Drugs (Anti-obesity Medication) Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 78. Vivus Anti-Obesity Drugs (Anti-obesity Medication) Product
Table 79. Vivus Recent Developments/Updates
Table 80. Shionogi Corporation Information
Table 81. Shionogi Description and Business Overview
Table 82. Shionogi Anti-Obesity Drugs (Anti-obesity Medication) Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 83. Shionogi Anti-Obesity Drugs (Anti-obesity Medication) Product
Table 84. Shionogi Recent Developments/Updates
Table 85. Sanofi Corporation Information
Table 86. Sanofi Description and Business Overview
Table 87. Sanofi Anti-Obesity Drugs (Anti-obesity Medication) Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 88. Sanofi Anti-Obesity Drugs (Anti-obesity Medication) Product
Table 89. Sanofi Recent Developments/Updates
Table 90. Rhythm Pharmaceuticals Corporation Information
Table 91. Rhythm Pharmaceuticals Description and Business Overview
Table 92. Rhythm Pharmaceuticals Anti-Obesity Drugs (Anti-obesity Medication) Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 93. Rhythm Pharmaceuticals Anti-Obesity Drugs (Anti-obesity Medication) Product
Table 94. Rhythm Pharmaceuticals Recent Developments/Updates
Table 95. Pfizer Corporation Information
Table 96. Pfizer Description and Business Overview
Table 97. Pfizer Anti-Obesity Drugs (Anti-obesity Medication) Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 98. Pfizer Anti-Obesity Drugs (Anti-obesity Medication) Product
Table 99. Pfizer Recent Developments/Updates
Table 100. Orexigen Therapeutics Corporation Information
Table 101. Orexigen Therapeutics Description and Business Overview
Table 102. Orexigen Therapeutics Anti-Obesity Drugs (Anti-obesity Medication) Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 103. Orexigen Therapeutics Anti-Obesity Drugs (Anti-obesity Medication) Product
Table 104. Orexigen Therapeutics Recent Developments/Updates
Table 105. Novo Nordisk Corporation Information
Table 106. Novo Nordisk Description and Business Overview
Table 107. Novo Nordisk Anti-Obesity Drugs (Anti-obesity Medication) Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 108. Novo Nordisk Anti-Obesity Drugs (Anti-obesity Medication) Product
Table 109. Novo Nordisk Recent Developments/Updates
Table 110. Norgine Corporation Information
Table 111. Norgine Description and Business Overview
Table 112. Norgine Anti-Obesity Drugs (Anti-obesity Medication) Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 113. Norgine Anti-Obesity Drugs (Anti-obesity Medication) Product
Table 114. Norgine Recent Developments/Updates
Table 115. Nalpropion Pharmaceuticals Inc. Corporation Information
Table 116. Nalpropion Pharmaceuticals Inc. Description and Business Overview
Table 117. Nalpropion Pharmaceuticals Inc. Anti-Obesity Drugs (Anti-obesity Medication) Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 118. Nalpropion Pharmaceuticals Inc. Anti-Obesity Drugs (Anti-obesity Medication) Product
Table 119. Nalpropion Pharmaceuticals Inc. Recent Developments/Updates
Table 120. Merck Corporation Information
Table 121. Merck Description and Business Overview
Table 122. Merck Anti-Obesity Drugs (Anti-obesity Medication) Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 123. Merck Anti-Obesity Drugs (Anti-obesity Medication) Product
Table 124. Merck Recent Developments/Updates
Table 125. GlaxoSmithKline Corporation Information
Table 126. GlaxoSmithKline Description and Business Overview
Table 127. GlaxoSmithKline Anti-Obesity Drugs (Anti-obesity Medication) Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 128. GlaxoSmithKline Anti-Obesity Drugs (Anti-obesity Medication) Product
Table 129. GlaxoSmithKline Recent Developments/Updates
Table 130. F.Hoffmann-La Roche Corporation Information
Table 131. F.Hoffmann-La Roche Description and Business Overview
Table 132. F.Hoffmann-La Roche Anti-Obesity Drugs (Anti-obesity Medication) Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 133. F.Hoffmann-La Roche Anti-Obesity Drugs (Anti-obesity Medication) Product
Table 134. F.Hoffmann-La Roche Recent Developments/Updates
Table 135. Eisai Corporation Information
Table 136. Eisai Description and Business Overview
Table 137. Eisai Anti-Obesity Drugs (Anti-obesity Medication) Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 138. Eisai Anti-Obesity Drugs (Anti-obesity Medication) Product
Table 139. Eisai Recent Developments/Updates
Table 140. Boehringer Ingelheim Corporation Information
Table 141. Boehringer Ingelheim Description and Business Overview
Table 142. Boehringer Ingelheim Anti-Obesity Drugs (Anti-obesity Medication) Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 143. Boehringer Ingelheim Anti-Obesity Drugs (Anti-obesity Medication) Product
Table 144. Boehringer Ingelheim Recent Developments/Updates
Table 145. Bayer AG Corporation Information
Table 146. Bayer AG Description and Business Overview
Table 147. Bayer AG Anti-Obesity Drugs (Anti-obesity Medication) Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 148. Bayer AG Anti-Obesity Drugs (Anti-obesity Medication) Product
Table 149. Bayer AG Recent Developments/Updates
Table 150. AstraZeneca Corporation Information
Table 151. AstraZeneca Description and Business Overview
Table 152. AstraZeneca Anti-Obesity Drugs (Anti-obesity Medication) Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 153. AstraZeneca Anti-Obesity Drugs (Anti-obesity Medication) Product
Table 154. AstraZeneca Recent Developments/Updates
Table 155. Arena Pharmaceuticals Corporation Information
Table 156. Arena Pharmaceuticals Description and Business Overview
Table 157. Arena Pharmaceuticals Anti-Obesity Drugs (Anti-obesity Medication) Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 158. Arena Pharmaceuticals Anti-Obesity Drugs (Anti-obesity Medication) Product
Table 159. Arena Pharmaceuticals Recent Developments/Updates
Table 160. Amylin Corporation Information
Table 161. Amylin Description and Business Overview
Table 162. Amylin Anti-Obesity Drugs (Anti-obesity Medication) Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 163. Amylin Anti-Obesity Drugs (Anti-obesity Medication) Product
Table 164. Amylin Recent Developments/Updates
Table 165. Alizyme Corporation Information
Table 166. Alizyme Description and Business Overview
Table 167. Alizyme Anti-Obesity Drugs (Anti-obesity Medication) Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2019-2024)
Table 168. Alizyme Anti-Obesity Drugs (Anti-obesity Medication) Product
Table 169. Alizyme Recent Developments/Updates
Table 170. Key Raw Materials Lists
Table 171. Raw Materials Key Suppliers Lists
Table 172. Anti-Obesity Drugs (Anti-obesity Medication) Distributors List
Table 173. Anti-Obesity Drugs (Anti-obesity Medication) Customers List
Table 174. Anti-Obesity Drugs (Anti-obesity Medication) Market Trends
Table 175. Anti-Obesity Drugs (Anti-obesity Medication) Market Drivers
Table 176. Anti-Obesity Drugs (Anti-obesity Medication) Market Challenges
Table 177. Anti-Obesity Drugs (Anti-obesity Medication) Market Restraints
Table 178. Research Programs/Design for This Report
Table 179. Key Data Information from Secondary Sources
Table 180. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Anti-Obesity Drugs (Anti-obesity Medication)
Figure 2. Global Anti-Obesity Drugs (Anti-obesity Medication) Market Value Comparison by Type (2024-2030) & (US$ Million)
Figure 3. Global Anti-Obesity Drugs (Anti-obesity Medication) Market Share by Type in 2023 & 2030
Figure 4. Prescription Drugs Product Picture
Figure 5. OTC Drugs Product Picture
Figure 6. Global Anti-Obesity Drugs (Anti-obesity Medication) Market Value Comparison by Application (2024-2030) & (US$ Million)
Figure 7. Global Anti-Obesity Drugs (Anti-obesity Medication) Market Share by Application in 2023 & 2030
Figure 8. Childhood (0-6)
Figure 9. Juvenile (7-17)
Figure 10. Youth (18-40)
Figure 11. Middle Aged (41-60)
Figure 12. Elderly (Above 60)
Figure 13. Global Anti-Obesity Drugs (Anti-obesity Medication) Revenue, (US$ Million), 2019 VS 2023 VS 2030
Figure 14. Global Anti-Obesity Drugs (Anti-obesity Medication) Market Size (2019-2030) & (US$ Million)
Figure 15. Global Anti-Obesity Drugs (Anti-obesity Medication) Sales (2019-2030) & (K Units)
Figure 16. Global Anti-Obesity Drugs (Anti-obesity Medication) Average Price (USD/Unit) & (2019-2030)
Figure 17. Anti-Obesity Drugs (Anti-obesity Medication) Report Years Considered
Figure 18. Anti-Obesity Drugs (Anti-obesity Medication) Sales Share by Manufacturers in 2023
Figure 19. Global Anti-Obesity Drugs (Anti-obesity Medication) Revenue Share by Manufacturers in 2023
Figure 20. The Global 5 and 10 Largest Anti-Obesity Drugs (Anti-obesity Medication) Players: Market Share by Revenue in 2023
Figure 21. Anti-Obesity Drugs (Anti-obesity Medication) Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2019 VS 2023
Figure 22. Global Anti-Obesity Drugs (Anti-obesity Medication) Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Figure 23. North America Anti-Obesity Drugs (Anti-obesity Medication) Sales Market Share by Country (2019-2030)
Figure 24. North America Anti-Obesity Drugs (Anti-obesity Medication) Revenue Market Share by Country (2019-2030)
Figure 25. U.S. Anti-Obesity Drugs (Anti-obesity Medication) Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 26. Canada Anti-Obesity Drugs (Anti-obesity Medication) Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 27. Europe Anti-Obesity Drugs (Anti-obesity Medication) Sales Market Share by Country (2019-2030)
Figure 28. Europe Anti-Obesity Drugs (Anti-obesity Medication) Revenue Market Share by Country (2019-2030)
Figure 29. Germany Anti-Obesity Drugs (Anti-obesity Medication) Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 30. France Anti-Obesity Drugs (Anti-obesity Medication) Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 31. U.K. Anti-Obesity Drugs (Anti-obesity Medication) Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 32. Italy Anti-Obesity Drugs (Anti-obesity Medication) Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 33. Russia Anti-Obesity Drugs (Anti-obesity Medication) Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 34. Asia Pacific Anti-Obesity Drugs (Anti-obesity Medication) Sales Market Share by Region (2019-2030)
Figure 35. Asia Pacific Anti-Obesity Drugs (Anti-obesity Medication) Revenue Market Share by Region (2019-2030)
Figure 36. China Anti-Obesity Drugs (Anti-obesity Medication) Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 37. Japan Anti-Obesity Drugs (Anti-obesity Medication) Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 38. South Korea Anti-Obesity Drugs (Anti-obesity Medication) Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 39. India Anti-Obesity Drugs (Anti-obesity Medication) Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 40. Australia Anti-Obesity Drugs (Anti-obesity Medication) Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 41. China Taiwan Anti-Obesity Drugs (Anti-obesity Medication) Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 42. Indonesia Anti-Obesity Drugs (Anti-obesity Medication) Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 43. Thailand Anti-Obesity Drugs (Anti-obesity Medication) Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 44. Malaysia Anti-Obesity Drugs (Anti-obesity Medication) Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 45. Latin America Anti-Obesity Drugs (Anti-obesity Medication) Sales Market Share by Country (2019-2030)
Figure 46. Latin America Anti-Obesity Drugs (Anti-obesity Medication) Revenue Market Share by Country (2019-2030)
Figure 47. Mexico Anti-Obesity Drugs (Anti-obesity Medication) Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 48. Brazil Anti-Obesity Drugs (Anti-obesity Medication) Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 49. Argentina Anti-Obesity Drugs (Anti-obesity Medication) Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 50. Middle East & Africa Anti-Obesity Drugs (Anti-obesity Medication) Sales Market Share by Country (2019-2030)
Figure 51. Middle East & Africa Anti-Obesity Drugs (Anti-obesity Medication) Revenue Market Share by Country (2019-2030)
Figure 52. Turkey Anti-Obesity Drugs (Anti-obesity Medication) Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 53. Saudi Arabia Anti-Obesity Drugs (Anti-obesity Medication) Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 54. UAE Anti-Obesity Drugs (Anti-obesity Medication) Revenue Growth Rate (2019-2030) & (US$ Million)
Figure 55. Global Sales Market Share of Anti-Obesity Drugs (Anti-obesity Medication) by Type (2019-2030)
Figure 56. Global Revenue Market Share of Anti-Obesity Drugs (Anti-obesity Medication) by Type (2019-2030)
Figure 57. Global Anti-Obesity Drugs (Anti-obesity Medication) Price (USD/Unit) by Type (2019-2030)
Figure 58. Global Sales Market Share of Anti-Obesity Drugs (Anti-obesity Medication) by Application (2019-2030)
Figure 59. Global Revenue Market Share of Anti-Obesity Drugs (Anti-obesity Medication) by Application (2019-2030)
Figure 60. Global Anti-Obesity Drugs (Anti-obesity Medication) Price (USD/Unit) by Application (2019-2030)
Figure 61. Anti-Obesity Drugs (Anti-obesity Medication) Value Chain
Figure 62. Anti-Obesity Drugs (Anti-obesity Medication) Production Process
Figure 63. Channels of Distribution (Direct Vs Distribution)
Figure 64. Distributors Profiles
Figure 65. Bottom-up and Top-down Approaches for This Report
Figure 66. Data Triangulation
Figure 67. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
